GlyH-101

Catalog No.S8094 Batch:S809401

Print

Technical Data

Formula

C19H15Br2N3O3
Molecular Weight 493.15 CAS No. 328541-79-3
Solubility (25°C)* In vitro DMSO 98 mg/mL (198.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
4.9mg/ml Taking the 1 mL working solution as an example, add 50 μL of 98 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.81mg/ml Taking the 1 mL working solution as an example, add 50 μL of 16.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description GlyH-101 is a selective and reversible CFTR inhibitor with Ki of 4.3 μM.
Targets
CFTR [1]
4.3 μM(Ki)
In vitro GlyH-101 reversibly inhibits CFTR Cl- conductance in <1 min. [1] In rabbit isolated ventricular myocytes, GlyH-101 also blocks cardiac I(Cl.PKA) channels. [2] In transfected FRT (SLC26A9-FRT) cells, GlyH-101 inhibits SLC26A9-mediated Cl- currents. [3]
In vivo In mice, Topical GlyH-101 (10 μM) in mice rapidly and reversibly inhibits forskolin-induced hyperpolarization in nasal potential differences. In a cholera model, intraluminal GlyH-101 (2.5 μg) reduces cholera toxin-induced intestinal fluid secretion by approximately 80%.[1]

Protocol (from reference)

Animal Study:

[1]
  • Animal Models

    CD1 mice

  • Dosages

    10 μM

  • Administration

    Topical treatment

Selleck's GlyH-101 has been cited by 3 publications

The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of Aspergillus fumigatus biofilms [ mBio, 2023, 14(5):e0151623] PubMed: 37830825
The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of Aspergillus fumigatus biofilms [ mBio, 2023, 14(5):e0151623] PubMed: 37830825
CFTR is a negative regulator of γδ T cell IFN-γ production and antitumor immunity [ Cell Mol Immunol, 2020, 10.1038/s41423-020-0499-3] PubMed: 32669666

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.